By: Benzinga
UPDATE: Citigroup Upgrades Biogen Idec to Buy on Strong Fundamentals
Citigroup upgraded Biogen Idec (NASDAQ: BIIB ) from Neutral to Buy and raised the price target from $160.00 to $187.00. Citigroup commented, "We are upgrading Biogen to Buy as we simply do not see a better entry point anytime soon. We have been on the sidelines hoping to find material
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here